Every S-1 that Wellgistics Health Inc. (WGRX) has filed with the SEC in the last 12 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A S-1 covers the registration statement a company files to sell shares publicly, so if you follow WGRX and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full WGRX filings page.
DataMeds AI, Inc. is registering 34,462,058 shares of common stock for resale by existing selling stockholders. The shares consist of previously issued stock, shares issuable from May 2026 convertible notes and related Series A preferred stock, and shares underlying PIPE and placement agent warrants. The company itself is not selling stock and will receive no proceeds from these resales, only potential cash from any future PIPE or placement agent warrant exercises.
These financings use variable conversion prices, floors as low as $1.00 per share, and Series A preferred stock with a 10% annual dividend added to stated value, which can substantially increase shares issued over time. With 2,847,198 shares outstanding as of July 27, 2026, the company estimates up to 36,027,113 shares could be outstanding if all May 2026 notes convert at $1.00 and all PIPE and placement agent warrants are exercised, implying significant dilution. DataMeds operates a micro health ecosystem combining wholesale distribution, a technology hub platform and a multi‑state pharmacy. It recently completed a 1‑for‑50 reverse split to regain Nasdaq’s $1.00 bid requirement and is working to restore compliance with Nasdaq’s $2.5 million stockholders’ equity standard by October 12, 2026.
Wellgistics Health, Inc. is amending its S-1 registration to offer up to 5,357,142 shares of Common Stock at an assumed public offering price of $1.40 per share. After the offering (and assuming full exercise of any Pre-Funded Warrants and no exercise of accompanying Warrants) the company would have 89,621,242 shares outstanding. The filing discloses a recent acquisition (Wellgistics) with pro forma recognition of substantial goodwill and intangible assets and transaction consideration that included a cash component and issuance of 3,999,335 restricted shares valued at $15,000,000.
The company reported consolidated losses in the periods presented, including a combined net loss of $39,103,367 (weighted average shares 56,863,720, net loss per share $0.69) and other historical net losses (for a prior period of $10,592,215). The pro forma balance sheet includes a note payable originally $15,000,000 that was amended to a principal of $17,500,000 payable in installments. The filing also discloses a U.S. utility patent application titled "Method and Apparatus for Prescription Management."